Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05103683 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
A Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, sponsored by TORL Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT05103683: Recruiting Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, sponsored by TORL Biotherapeutics.
NCT05103683 is a Phase 1 study of Ovarian Cancer and Advanced Solid Tumor that is actively recruiting participants, run by TORL Biotherapeutics. The registered enrollment target is 90 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05103683, a Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by TORL Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Primary Outcome
Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0
Conditions Studied
Interventions
- DRUG TORL-1-23
Study Locations (14)
Other
- Seoul National University Hospital - Seoul
- Severance Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
California
- Providence Medical Foundation - Fullerton
- UCLA - JCCC Clinical Research Unit - Los Angeles
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic in Rochester - Rochester
Kentucky
- University of Kentucky Medical Center - Lexington
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
Texas
- Sarah Cannon Research Institute Texas Oncology - Tyler
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2026-11-15 |
| Phase | Phase 1 |
What NCT05103683 shows while recruiting
NCT05103683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which TORL-1-23 is the first listed.
NCT05103683 lists 14 locations in 9 states (Other, California, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05103683 about?
NCT05103683 is a clinical study titled "First in Human Study of TORL-1-23 in Participants With Advanced Cancer". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
What is the current status of trial NCT05103683?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2021-11-17. Estimated completion is 2026-11-15.
What conditions does trial NCT05103683 study?
This clinical trial studies the following conditions: Ovarian Cancer, Advanced Solid Tumor, Endometrial Cancer, NSCLC.
What interventions are being tested in trial NCT05103683?
The interventions under investigation include: TORL-1-23 (DRUG).
Who is sponsoring clinical trial NCT05103683?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05103683 being conducted?
This trial has 14 study locations across California, Kentucky, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05103683's enrollment target sits among peer trials
90 156th of 322 higher than 162 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI